United Kingdom
Michael joined Lhasa in 2015 working on the Mirabilis project, aiding the research and curation of knowledge relevant to understanding the potential for purging of mutagenic impurities from drug substance syntheses. In 2017, he took over leadership of Mirabilis development and has since been working closely with leading members of the purge calculation community to develop Mirabilis and the purge concept, including more recently their impact on the ongoing nitrosamine challenges.
